InMed Pharmaceuticals Inc. INM
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -26.22% | -11.43% | 1.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -26.22% | -11.43% | 1.68% |
| Cost of Revenue | -- | -- | -2.27% | -7.03% | -- |
| Gross Profit | -- | -- | -60.03% | -18.28% | -- |
| SG&A Expenses | 87.21% | 9.95% | -5.68% | 2.61% | -28.52% |
| Depreciation & Amortization | -7.28% | 0.00% | 0.00% | -2.56% | -4.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.04% | 36.62% | -11.37% | -4.48% | -42.64% |
| Operating Income | -70.04% | -36.62% | 3.88% | -0.54% | 6.00% |
| Income Before Tax | -163.99% | -35.06% | 21.23% | -2.92% | 4.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -163.99% | -35.06% | 21.23% | -2.92% | 5.32% |
| Earnings from Discontinued Operations | -2,251.84% | -223.93% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -226.53% | -39.86% | 21.23% | -2.92% | 7.71% |
| EBIT | -70.04% | -36.62% | 3.88% | -0.54% | 6.00% |
| EBITDA | -72.07% | -37.66% | 3.98% | -0.64% | 5.94% |
| EPS Basic | 8.74% | 62.13% | 85.93% | 83.86% | 70.32% |
| Normalized Basic EPS | 51.42% | 63.44% | 85.93% | 83.86% | 69.44% |
| EPS Diluted | 8.74% | 62.13% | 85.93% | 83.86% | 70.32% |
| Normalized Diluted EPS | 51.42% | 63.44% | 85.93% | 83.86% | 69.44% |
| Average Basic Shares Outstanding | 257.82% | 269.36% | 459.73% | 537.72% | 210.94% |
| Average Diluted Shares Outstanding | 257.82% | 269.36% | 459.73% | 537.72% | 210.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |